In MASLD, females exhibit higher hepatic IL-22 expression, and the absence of IL-22RA1 signaling worsens hepatic pathology more severely in females (Abdelnabi et al., 2022). This evidence concerns the gene IL22 and metabolic dysfunction-associated steatotic liver disease.